CHARIOT

Closed

BCT 1702: CHARIOT

BCT Study Chair:

Sherene Loi

An Australian clinical trial open to both women and men diagnosed with unilateral triple negative early breast cancer. The CHARIOT clinical trial will investigate if using Immunotherapy drugs together with standard chemotherapy is safe and effective in treating breast cancer before surgery, and if continuing immunotherapy after surgery keeps the immune system active.

0

INTERNATIONAL

Total number of trial

participants internationally

34

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

13

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

CHARIOT PUBLICATIONS

2022

Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.

Loi S, Francis PA, Zdenkowski N, Gebski V, Fox SB, White M, Kiely BE, Woodward NE, Hui R, Redfern AD, Calvert R, Rennie L, Boyle FM. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #602, Abstract

2018

BCT1702 CHARIOT: Checkpoint Therapy in Triple Negative Breast Cancer – Trial in Progress. [MOGA 2018 – Poster].

Zdenkowski N, Loi S, Francis P, Gebski V, Badger H, Boyle F. Asia-Pacific Journal of Clinical Oncology. 2018; 14(53):74, Poster

CHARIOT